Share Twitter LinkedIn Facebook Email Toni K. Choueiri Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute presents Savolitinib (volitinib, AZD6094, HMPL-504): Future Directions at the 2016 annual International Kidney Cancer Symposium. Advertisement
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read